Liberum Capital Has Just Reaffirmed GBX 600.00 Target Price Per Share on PureCircle Ltd (LON:PURE) stock, While They’ve Also Reiterated Their “Buy” Rating


PureCircle Ltd (LON:PURE) Rating Reaffirmed

The investment house has just set a price target of GBX 600.00 on PureCircle Ltd (LON:PURE) shares. This is 52.48% from the stock close price. In a very recent research note issued to clients and investors on Monday morning, Liberum Capital reconfirmed their “Buy” rating on shares of PURE.

From a total of 4 analysts covering PureCircle Ltd (LON:PURE) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is GBX 9.1 while the lowest target price is GBX 7.6. The mean of all analyst targets is GBX 8.7 with a 37.50% above today’s (GBX 400) stock price. PureCircle Ltd was the topic of 18 analyst reports since July 27, 2015 according to the firm StockzIntelligence Inc. Liberum Capital maintained shares on December 14 with “Buy” rating.

Approximately 4,626 shares of stock traded hands. PureCircle Limited (LON:PURE) has declined 12.54% since May 15, 2015 and is downtrending. It has underperformed by 8.13% the S&P500.

Liberum Capital Has Just Reaffirmed GBX 600.00 Target Price Per Share on PureCircle Ltd (LON:PURE) stock, While They’ve Also Reiterated Their

PureCircle Limited is a Malaysia-based investment holding company. The company has a market cap of 688.36 million GBP. The Company, through its subsidiaries, engages in production, distribution, sales and marketing of natural sweeteners and flavours; investment holding; supply and development of stevia agronomy, and supply chain, production and distribution of natural sweeteners and flavours. It has 248.6 P/E ratio. The Company’s sweeteners include stevia, which includes Reb A, SG95, Sweta and PureCirce Alpha, and flavors include PureCircle flavours.

According to Zacks Investment Research, “PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of green products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.”